Clinical trials · New York, NY
Neoplasms clinical trials in New York
We’re tracking 194 recruiting neoplasms studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05419518RecruitingPhase 2
Higher-dose radiation to ease pain from metastatic tumors
This Phase 2 study tests whether a stronger (higher-dose) radiation plan can better reduce pain from tumors that have spread to bone or other areas. It’s meant to help people live more comfortably by targeting painful spots while avoiding certain high-risk situations.
Livingston, New JerseyAges 18 years+ - NCT06807437RecruitingPhase 3
Testing lanreotide before pancreas surgery to prevent leaks
This trial tests if a medicine called lanreotide, given before surgery, can prevent a common complication (pancreatic leak) after removing part of the pancreas. It is for people with pancreatic cancer or a growth that could become cancer who are scheduled for a specific type of pancreas surgery.
Livingston, New JerseyAges 18 years+ - NCT07677267Recruiting
Study of treatment patterns and outcomes for advanced prostate cancer patients
This study looks at real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) who have already used certain treatments, including a newer drug called lutetium-177 PSMA-617. It aims to understand how these treatments work and what happens to patients over time.
East Hanover, New JerseyAges 18–115 - NCT07677254Recruiting
Real world study of prostate cancer treatments
This study looks at real-world data from men with metastatic castration-resistant prostate cancer (mCRPC) to understand what treatments they receive and how they do. It may help doctors learn more about which treatments work best.
East Hanover, New JerseyAges 18–115 - NCT04068649RecruitingPhase 2
Single high-dose radiation vs standard palliative radiation
This Phase 2 study compares a one-time, high-dose radiation treatment (SBRT) with the usual, shorter-course palliative radiation. The goal is to see which approach better relieves symptoms from metastatic (spread) cancer.
East Hills, New YorkAges 18 years+ - NCT03463954Recruiting
Laser treatment trial for small breast tumors
This trial tests a focused laser treatment (Novilase®) to destroy small, cancerous breast tumors while aiming to work with standard care. It may help people who have an early, localized tumor that can be clearly seen on imaging so doctors can guide the laser safely.
Florham Park, New JerseyAges 18 years+ - NCT06388967Recruiting
Pancreatic cancer detection study
This study is looking at blood or tissue samples from people with pancreatic cancer and from those without it. The goal is to find ways to detect the cancer earlier.
Morristown, New JerseyAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
New Brunswick, New JerseyAges 18 years+ - NCT07165691Recruiting
Lung cancer screening coaching for Hispanic patients
This trial tests a program that helps Hispanic and Latino patients make informed decisions about lung cancer screening. It uses a coaching approach to support you and your doctor in choosing the best next steps.
New Brunswick, New JerseyAges 50–77 - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
New Brunswick, New JerseyAges 18 years+ - NCT07209111RecruitingPhase 2
Testing Calderasib for advanced solid tumors with KRAS G12C mutation
This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.
New Brunswick, New JerseyAges 18 years+ - NCT06686394RecruitingPhase 1/Phase 2
New drug combo for HER2+ breast cancer that has spread
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
New Brunswick, New JerseyAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
New Brunswick, New JerseyAges 18 years+ - NCT05491213Recruiting
Telehealth coaching to help decide on lung cancer screening
This trial tests a telehealth (video/phone) coaching program that helps people and their primary care teams make shared decisions about lung cancer screening. It may help you understand the benefits and downsides before choosing whether to get screened.
New Brunswick, New JerseyAges 18 years+ - NCT06990880RecruitingPhase 1/Phase 2
Study of GSK5458514 alone or with other drugs for prostate cancer
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
East Brunswick, New JerseyAges 18 years+ - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
East Brunswick, New JerseyAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Greenwich, ConnecticutAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Voorhees Township, New JerseyAges 18 years+ - NCT04329494RecruitingPhase 1
Study of targeted drug delivery into the abdomen using PIPAC
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Greenlawn, New YorkAges 18 years+ - NCT04185935Recruiting
Genetic study of cancer in patients and their families
This study looks at DNA patterns in families where cancer may run in families, to better understand inherited (passed-down) cancer risk. You may be able to help even if you’re not sure whether your cancer is genetic—your family history and, if needed, medical records or tumor samples can be used.
Mount Kisco, New YorkAges Any age - NCT04406831Recruiting
Testing microRNA for pancreatic cancer diagnosis and treatment response
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Norwalk, ConnecticutAges 18 years+ - NCT03250078Recruiting
Pancreatic cancer screening for people at high genetic risk
This study offers pancreatic cancer screening for people with strong family history or certain inherited gene changes. It may help find pancreatic cancer earlier, when treatment may be more effective.
Norwalk, ConnecticutAges 50–90 - NCT03937453Recruiting
Pancreatic cancer screening for people with new or worsening diabetes
This study checks whether regular imaging can find pancreatic cancer earlier in people who recently developed diabetes or whose diabetes is getting worse. It may help detect pancreatic problems sooner when treatment options are likely better.
Norwalk, ConnecticutAges 50 years+
Hear when a new Neoplasms trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Neoplasms trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting neoplasms studies listed above.
- Rutgers Cancer Institute of New Jersey · 9 studies
- Nuvance Health · 3 studies
- Cooperman Barnabas Medical Center · 2 studies
- GSK Investigational Site · 2 studies
- Novartis · 2 studies
- Atlantic Health System
- Community Medical Center
- Good Samaritan University Hospital
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neoplasms studies in New York.
Common questions
- Are there neoplasms clinical trials near New York?
- Yes. We're currently tracking 194 recruiting neoplasms studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.